Drugs / Sindilimab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06140576 | Nov 2023 → Dec 2025 overdue | breast neoplasm | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04997850 | Oct 2020 → May 2022 | hepatocellular carcinoma | Xinrui Zhu，MD | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04799639 | Mar 2021 → Jun 2024 | cervical cancer, chemotherapy-induced toxicity | Sun Yat-sen University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sindilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06140576 ↗ |
| Route | Intravenous | “intravenous drip of standard dose paclitaxel + cisplantin + Sindilimab” NCT04799639 ↗ |